Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 1, 2016 (10 years ago)

Zinc Acetate

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Does not meet monograph: product exhibits lead levels in excess of the USP monograph limits.

Cause type: Unapproved drug

The product was marketed without an approved NDA/ANDA, or does not meet the OTC monograph it claims to follow. Nothing about the product - dose, purity, safety - has been reviewed by FDA, so the claims on the box are unverified. All unapproved drug recalls.

What was recalled

Zinc Acetate, Crystal, USP, packaged in 500 gram bottles, Spectrum Chemical MFG, CORP., New Brunswick, NJ 08901

Drug: Zinc

Recalling firm
Spectrum Laboratory Products, Inc.
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1456-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zinc recalls

See all
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026

Other recalls by Spectrum Laboratory Products, Inc.

All 2016 recalls
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0180-2023
Class I · High risk

Epinephrine

Discoloration: Product complaints of the repackaged Epinephrine API being discolored which could result in less effective product

Terminated Failed specification Spectrum Laboratory Products, Inc. D-0179-2023
Class II · Moderate risk

Estriol

Subpotent Drug: Supplier indicated assay results did not meet specifications.

Terminated Wrong potency / content Spectrum Laboratory Products D-0628-2020